Today: 7 February 2026
Subscribe
Browse Category

Mergers & Acquisitions News 12 November 2025 - 18 November 2025

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Summary Live PFE snapshot (intraday) New today: Pfizer sells debt to fund Metsera Pfizer began marketing a U.S. dollar investment‑grade bond expected to raise at least $5 billion, with the deal structured in as many as seven parts. Early discussions include a 40‑year tranche initially talked around ~125 bps over Treasuries, according to Bloomberg reporting on the transaction. A separate Reuters alert flagged a seven‑part notes offering in a fresh SEC filing, with sizing to be finalized at pricing. Together, the moves point to active balance‑sheet management following the Metsera close. Bloomberg Law+1 Why it matters: reading the financing signal
18 November 2025
·····
Blue Owl’s BDC Shake‑Up (Nov. 17, 2025): OBDC–OBDC II Merger Puts ~20% Haircut on the Table for Retail Holders—But Double‑Digit Yields Lure Value Buyers

Blue Owl’s BDC Shake‑Up (Nov. 17, 2025): OBDC–OBDC II Merger Puts ~20% Haircut on the Table for Retail Holders—But Double‑Digit Yields Lure Value Buyers

Published November 17, 2025 Summary: Blue Owl Capital is moving to fold its private Blue Owl Capital Corporation II (OBDC II) into the listed Blue Owl Capital Corporation (NYSE: OBDC). Because OBDC stock trades below its reported net asset value (NAV), today’s pricing implies roughly a 20% value hit for OBDC II investors at closing—though the combined BDC would be larger, more liquid and, at today’s price, offers a double‑digit dividend yield. Blue Owl Capital Corporation+2Blue Owl Capital Corporation+2 What’s new today (Nov. 17, 2025) The deal at a glance Why a ~20% hit is possible: the math in plain
17 November 2025
Clearwater Analytics (CWAN) Soars on Warburg Pincus & Permira Buyout Buzz — Key Updates for November 17, 2025

Clearwater Analytics (CWAN) Soars on Warburg Pincus & Permira Buyout Buzz — Key Updates for November 17, 2025

On Monday, November 17, 2025, Clearwater Analytics Holdings, Inc. (NYSE: CWAN) once again jumped onto traders’ radar as renewed buyout speculation from private equity giants Warburg Pincus and Permira pushed the stock sharply higher in pre‑market trading and kept it among the day’s notable movers. TradingView+2Benzinga+2 Below is a full rundown of what’s driving Clearwater Analytics today, how it fits into the company’s broader AI and growth story, and what investors are watching next. CWAN Stock Today: Double‑Digit Premarket Spike, Still Volatile Mid‑Session Clearwater Analytics shares extended last week’s rally in Monday’s pre‑market session: By late morning, the move had
17 November 2025
·
E.W. Scripps (SSP) Soars as Sinclair Builds 8.2% Stake and Pushes for Takeover on November 17, 2025

E.W. Scripps (SSP) Soars as Sinclair Builds 8.2% Stake and Pushes for Takeover on November 17, 2025

On November 17, 2025, Sinclair Inc. disclosed an 8.2% stake in The E.W. Scripps Company (NASDAQ: SSP) and confirmed it is pursuing a merger, sending SSP stock more than 20% higher. Here’s what the potential Sinclair–Scripps deal means for investors, the local TV landscape and sports rights. The E.W. Scripps Company (NASDAQ: SSP) is at the center of one of the biggest media storylines of 2025 after rival broadcaster Sinclair Inc. (NASDAQ: SBGI) revealed it has quietly built an 8.2% stake in Scripps’ Class A non‑voting shares and is actively pushing for a takeover.Reuters+1 The disclosure, made in a regulatory
17 November 2025
···
Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics Inc. (NASDAQ: RPTX) is back in the spotlight today after investors digested last week’s surprise acquisition agreement with XenoTherapeutics, Inc., a Massachusetts-based non‑profit biotech. The stock is trading sharply higher and unusually active as the market prices in a mostly cash takeover and a complex contingent value right (CVR) structure that could unlock additional upside over the coming decade. Repare Therapeutics+1 As of this afternoon’s session, RPTX is changing hands around the low‑$2 range, not far above the estimated US$1.82 per‑share cash consideration embedded in the deal, and up close to 30% versus pre‑announcement levels, reflecting a classic
17 November 2025
·
Ashurst–Perkins Coie Merger Creates $2.7 Billion Transatlantic Megafirm in Big Law Shake-Up

Ashurst–Perkins Coie Merger Creates $2.7 Billion Transatlantic Megafirm in Big Law Shake-Up

LONDON / SEATTLE — November 17, 2025 — London-headquartered Ashurst and US firm Perkins Coie have agreed to merge in a landmark transatlantic deal that will create a top‑20 global law firm with around 3,000 lawyers and annual revenue of about $2.7 billion. Operating under the new brand Ashurst Perkins Coie, the combined outfit will span 52 offices in 23 countries, cementing its status as one of the largest law firms in the world. Reuters+2Legal Cheek+2 A New Top‑20 Global Law Firm The merger is formally being described as a “combination of equals”, uniting two long‑established firms with more than
17 November 2025
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. (formerly NASDAQ: MTSR) is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted monopolization.” Here’s a full rundown of what matters today, 17 November 2025, for anyone following Metsera, MTSR, or the obesity‑drug arms race. 1. Where the Metsera–Pfizer Deal Stands Today Pfizer formally closed its acquisition of Metsera on November 13, 2025, after Metsera shareholders approved a sweetened offer that values the obesity biotech at up to $10 billion.Reuters+1 Key terms of
17 November 2025
·
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far.Reuters+1 The move deepens J&J’s bet on cancer medicines just as sales of its long‑time blockbuster psoriasis drug Stelara are being hit hard by a wave of cheaper biosimilar rivals.Yahoo Finance+1 Key points Inside Johnson & Johnson’s Halda Therapeutics takeover J&J said on Monday that it will acquire Halda Therapeutics for $3.05 billion in cash, adding a new set of precision oncology assets to its Innovative Medicine unit.Reuters+1
17 November 2025
··
TotalEnergies seals €5.1bn all‑stock JV for 50% of EPH’s flexible power portfolio, adding 14GW across Europe (17 Nov 2025)

TotalEnergies seals €5.1bn all‑stock JV for 50% of EPH’s flexible power portfolio, adding 14GW across Europe (17 Nov 2025)

PARIS — November 17, 2025. TotalEnergies has agreed to acquire a 50% stake in Energetický a průmyslový holding’s (EPH) flexible power generation platform in a €5.1 billion, all‑stock transaction. The deal creates a 50/50 joint venture spanning more than 14 gigawatts (GW) of gas‑fired, biomass and battery assets across Italy, the UK & Ireland, the Netherlands and France, with closing targeted for mid‑2026 pending approvals. EPH will be paid in newly issued TotalEnergies shares and become a meaningful shareholder in the French energy major. TotalEnergies.com+1 Key facts at a glance Why this deal matters For TotalEnergies, the acquisition accelerates a
17 November 2025
···
WPP Share Price Today: London Stock Jumps on Takeover Talk as FTSE 100 Exit Looms (17 November 2025)

WPP Share Price Today: London Stock Jumps on Takeover Talk as FTSE 100 Exit Looms (17 November 2025)

WPP’s London-listed shares staged a sharp rebound on Monday, 17 November 2025, as fresh takeover speculation and recent insider share buying tempted bargain hunters back into one of the UK market’s hardest‑hit blue chips. According to closing data from Hargreaves Lansdown, WPP plc (LON: WPP) ended the session at around 298p, up roughly 3.4% on the day, after trading between about 293p and 308p. That move adds to early‑morning gains that saw the stock jump more than 5% at one stage. Hargreaves Lansdown+1 Yet even after today’s bounce, the advertising group remains a shadow of its former self, with the share price down around 64% over
17 November 2025
··
Warner Bros Discovery Stock Skyrockets on $60B Takeover Rumors

Warner Bros. Discovery (WBD) Stock Climbs as Paramount, Comcast and Netflix Line Up Bids in High‑Stakes Auction – November 14, 2025

Warner Bros. Discovery, Inc. (NASDAQ: WBD) moved back into the spotlight on Friday, November 14, 2025, as a potential sale of all or part of the media giant appeared to crystallize into a three‑way contest between Paramount Skydance, Comcast and Netflix. The growing prospect of a bidding war sent WBD shares higher and intensified scrutiny of the company’s strategy, leadership and balance sheet. TradingView+3Sports Business Journal+3The Wall Street Journal+3 At the same time, new regulatory and governance angles emerged: a prominent U.S. lawmaker raised antitrust concerns about a possible Netflix deal, and Warner Bros. Discovery quietly rewrote CEO David Zaslav’s
14 November 2025
·····
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Cidara Therapeutics, Inc. (NASDAQ: CDTX) is at the center of Wall Street’s attention today after Merck & Co., Inc. (NYSE: MRK) agreed to acquire the San Diego–based biotech in a cash deal valued at approximately $9.2 billion, sending CDTX shares more than 100% higher in a single session. Reuters+1 Below is a detailed look at today’s news (14 November 2025), the science behind Cidara’s lead flu-prevention asset CD388, the stock market reaction, and the wave of shareholder-law-firm investigations that emerged within hours of the announcement. Merck to Acquire Cidara for $221.50 Per Share in Cash Merck and Cidara announced this
14 November 2025
··
Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Metsera Inc. (NASDAQ: MTSR) stops trading today, November 14, 2025, as Pfizer closes its up to $10 billion obesity-drug acquisition. Here’s what Metsera shareholders and obesity-market investors need to know about the deal terms, CVR, delisting, and future milestones. Date: November 14, 2025Ticker: MTSR (Metsera, Inc.) – now being delisted On Friday, November 14, 2025, Metsera, Inc. officially disappears from the Nasdaq tape. Trading in Metsera (NASDAQ: MTSR) has been suspended after Pfizer completed its acquisition of the obesity-focused biotech in a deal valued at up to $10 billion, capping one of the fiercest pharma bidding wars of the year.
14 November 2025
···
Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor, Inc. (NASDAQ: TRIP) returned to investors’ good graces on Friday after Mizuho upgraded the online travel company and lifted its price target, signaling Wall Street is starting to warm to an aggressive restructuring that includes layoffs, a Viator merger and a deeper bet on AI-powered travel experiences. Investing.com+1 As of mid‑day Friday, Tripadvisor shares were trading around $15.00, up roughly 1.5% from Thursday’s close at $14.78, though still well below their 52‑week high of $20.16. Investing.com+1 The bounce follows a bruising 6.75% slide on Thursday, when the stock sold off with the broader market despite recently reporting better‑than‑expected Q3
14 November 2025
···
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck & Co. (NYSE: MRK) has agreed to acquire Cidara Therapeutics (Nasdaq: CDTX) in a deal valued at about $9.2 billion, a blockbuster move that gives the pharma giant a late‑stage, long‑acting influenza prevention drug as it prepares for life after cancer juggernaut Keytruda. Reuters+1 Key points at a glance Deal terms: a rich premium for a single late‑stage asset Under the definitive agreement announced this morning, Merck will, through a subsidiary, launch a tender offer to purchase all outstanding shares of Cidara for $221.50 per share in cash. That price represents a 108.9% premium to Cidara’s last closing price
14 November 2025
·
Sealed Air (SEE) Soars to 52‑Week High as Clayton Dubilier & Rice Weighs Take‑Private Deal

Sealed Air (SEE) Soars to 52‑Week High as Clayton Dubilier & Rice Weighs Take‑Private Deal

Sealed Air Corporation (NYSE: SEE), maker of Bubble Wrap, jumped to a 52‑week high on November 13, 2025, as private‑equity firm Clayton Dubilier & Rice reportedly explores a take‑private deal. Here’s what’s driving SEE stock today, including fresh buyout rumors, Q3 2025 earnings, analyst targets, and key risks. Sealed Air Corporation (NYSE: SEE) is suddenly one of Wall Street’s hottest tickers. The packaging company behind Bubble Wrap and Cryovac is rallying sharply today after multiple reports that private‑equity giant Clayton, Dubilier & Rice (CD&R) is exploring a takeover that could take Sealed Air private. By late morning on Thursday, SEE
13 November 2025
·
Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (NASDAQ: MRSN) is back in the headlines in a big way today after announcing a definitive agreement to be acquired by Day One Biopharmaceuticals in a deal worth up to approximately $285 million. The news has sent MRSN shares rocketing higher and triggered immediate legal and regulatory attention, making this one of the most closely watched biotech deals of the day. GlobeNewswire Below is a complete roundup of today’s major developments around Mersana Therapeutics (MRSN) — structured and optimized for readers who find this via Google News or Discover. Today’s Mersana (MRSN) Headlines at a Glance – 13
13 November 2025
···
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Today, November 13, 2025: BioNTech Stake Sale, Metsera Deal and a 6%+ Dividend Put PFE Back in Focus

Pfizer stock (NYSE: PFE) is trading higher today as investors digest a fresh batch of headlines: a planned sale of the company’s remaining stake in Covid-19 vaccine partner BioNTech, ongoing reaction to its $10 billion Metsera obesity-drug deal, and renewed debate around whether PFE’s rich dividend compensates for its strategic risks. As of the latest quotes on Thursday, November 13, Pfizer shares are changing hands around $25.9, up roughly 1.4% on the day after trading between about $25.3 and $25.9 in today’s session. That puts the company’s market capitalization near $147 billion, with the stock still trading on a single-digit earnings multiple and yielding around 6.6–7% on a
13 November 2025
··
BP Stock Soars as Oil Rally and Strategic Shift Boost Investor Confidence

BP Nears Castrol Sale: Stonepeak in Advanced Talks as Valuation Swirls Around $8 Billion (Nov 13, 2025)

Published: November 13, 2025 Key points What’s new today Industry outlet Offshore Engineer reported in the early hours of Thursday that BP’s talks with Stonepeak are ongoing and part of a portfolio overhaul designed to meet the company’s $20 billion asset‑sale target. The update reiterates Reuters’ exclusive from late Wednesday and keeps Stonepeak at the front of the queue. oedigital.com+1 While neither BP nor Stonepeak has commented publicly, the cadence of coverage suggests the process is in a decisive phase. Reuters’ report adds that BP’s U.S. depositary receipts initially rose about 2% on the headline before easing—an indication investors see
13 November 2025
··
CMCT Stock Soars After $44M Sale of Lending Arm; CFO Transition and SBA Consent in Focus (Nov. 12, 2025)

CMCT Stock Soars After $44M Sale of Lending Arm; CFO Transition and SBA Consent in Focus (Nov. 12, 2025)

Published: November 12, 2025 What happened Creative Media & Community Trust Corporation (NASDAQ: CMCT) said today it has signed a definitive agreement to sell its lending division to PG FR Holding, LLC, an affiliate of the Atlanta‑based Peachtree Group. The deal value is approximately $44 million (net of certain securitization debt) and is expected to generate about $31 million in net cash to CMCT after debt paydowns and transaction costs, pending closing conditions. Business Wire Public markets applauded the move. CMCT shares ripped higher intraday—up roughly 66% around 12:24 p.m. ET—as traders digested the strategic divestiture and projected liquidity boost.
12 November 2025
1 … 12 13 14 15 16 … 20

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Go toTop